BioTime's Subsidiary Cell Cure Neurosciences, Ltd. Provides Update on OpRegen ... MarketWatch (press release) The use animal products to culture cells often results in the designation of the therapy as a "xenotransplantation" product, even though the cells themselves are of human origin. Xenotransplantation may raise purity issues, increasing the costs of ... BioTime's Subsidiary Cell Cure Neurosciences Provides Update on OpRegen ... |
